Insights into the interplay between Epstein‐Barr virus (EBV) and multiple sclerosis (MS): A state‐of‐the‐art review and implications for vaccine development
Open Access
- 15 February 2024
- journal article
- review article
- Published by Wiley in Health Science Reports
- Vol. 7 (2) , e1898
Abstract
Background and Aims: Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS). MS results from an inflammatory process leading to the loss of neural tissue and increased disability over time. The role of Epstein Barr Virus (EBV), as one of the most common global viruses, in MS development has been the subject of several studies. However, many related questions are still unanswered. This study aimed to review the connection between MS and EBV and provide a quick outline of MS prevention using EBV vaccination. Methods: For this narrative review, an extensive literature search using specific terms was conducted across online databases, including PubMed/Medline, Scopus, Web of Science, and Google Scholar, to identify pertinent studies. Results: Several studies proved that almost 100% of people with MS showed a history of EBV infection, and there was an association between high titers of EBV antibodies and an increased risk of MS development. Various hypotheses are proposed for how EBV may contribute to MS directly and indirectly: (1) Molecular Mimicry, (2) Mistaken Self, (3) Bystander Damage, and (4) Autoreactive B cells infected with EBV. Conclusion: Given the infectious nature of EBV and its ability to elude the immune system, EBV emerges as a strong candidate for being the underlying cause of MS. The development of an EBV vaccine holds promise for preventing MS; however, overcoming the challenge of creating a safe and efficacious vaccine presents a significant obstacle.Keywords
This publication has 99 references indexed in Scilit:
- Antiviral Treatment of Epstein-Barr Virus-Associated Lymphoproliferations2002
- Epstein-Barr Virus and Multiple SclerosisEpidemiology, 2000
- Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cellsBlood, 2000
- Expression of Epstein–Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccineVaccine, 1999
- Comparative evaluation of the use of immunoblots and of IgG avidity assays as confirmatory tests for the diagnosis of acute EBV infectionsJournal of Clinical Virology, 1998
- Molecular mimicry in T cell-mediated autoimmunity: Viral peptides activate human T cell clones specific for myelin basic proteinCell, 1995
- First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen.1995
- Multiple sclerosis: an autoimmune disease of multifactorial etiologyCurrent Opinion in Immunology, 1992
- Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.Journal of Experimental Medicine, 1992
- Annual incidence, prevalence, and mortality of multiple sclerosis in white South-African-born and in white immigrants to South Africa.BMJ, 1967